Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Bayer Receives FDA Approval for Room Temperature Storage of Kogenate FS (Antihemophilic Factor (Recombinant) Extended Storage Labeling Provides Greater Flexibility for Individuals Living with Hemophilia A BERKELEY, CA -- October 6, 2005 -- The Biological Products Division of Bayer HealthCare, LLC., (Bayer BP) announced today that Kogenate(R) FS (Antihemophilic Factor [Recombinant], Formulated with Sucrose) received approval to be stored at room temperature (77 degrees F, 25 degrees C) for up to three months. The new storage guidelines for the treatment will provide users with greater flexibility and simplify storage options. The United States Food and Drug Administration (FDA) approved the storage labeling change based on data from testing to assure the labeled potency (number of recombinant FVIII units contained in a vial) remains within specified limits through the expiration date of the product. The room temperature storage option is expected to be a significant convenience for Kogenate(R) FS users. Starting in November 2005, each package of Kogenate(R) FS will include a special notification with details on the new labeling. While the new room temperature storage option may be used, Bayer recommends refrigerating (36 degrees - 46 degrees F, 2 degrees - 8 degrees C) Kogenate(R) FS whenever possible. It also is important to note that product stored at room temperature should not be returned to refrigeration. Kogenate(R) FS users who may have additional questions about storage requirements for their existing product inventory should call Bayer Clinical Communications at 800-288-8371 (option 3). "We are pleased with the approval and the opportunity to provide our customers with this convenience," said Terry Tenbrunsel, Vice President, Sales and Marketing, Bayer BP. "Room temperature storage will be a great addition to our overall Kogenate(R) FS product offering. Along with other product features such as the 2.5 mL low volume diluent and the EZ-Log handheld electronic patient diary, this new labeling will provide greater freedom and allow individuals with hemophilia A to lead full, active, and productive lives." About Kogenate(R) FS Kogenate(R) FS (antihemophilic factor (recombinant), formulated with sucrose), is a recombinant factor VIII treatment for hemophilia A that offers a more convenient administration by utilizing a 2.5 mL volume diluent, one of the smallest among available factor VIII products. Kogenate(R) FS does not use albumin in its purification or formulation and includes a solvent/detergent viral inactivation step. Kogenate(R) FS is manufactured at Bayer BPs state-of-the-art biotechnology facility in Berkeley, Calif. The most frequently reported adverse event was local injection site reactions. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate(R) FS. About Hemophilia Hemophilia is an inherited bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. About 17,000 Americans have hemophilia. The disease is caused by deficient or defective blood coagulation proteins, known as factor VIII or IX. The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX. SOURCE: Bayer Biological Products E-mail this page to a friend or colleague! To print, use this version